News
-
Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company… Read more . . .
-
GlaxoSmithKline and Theravance have withdrawn the application for their fluticasone furoate/vilanterol DPI for the treatment of COPD from the Japanese New Drug Application (JNDA) for the drug, the companies say. Review of the JNDA, which… Read more . . .
-
GlaxoSmithKline has announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved for the treatment of COPD in Canada. GlaxoSmithKline Inc. President Paul Lirette said, “For over forty years, GlaxoSmithKline has been at the… Read more . . .
-
Inhaler testing automation supplier Astech Projects is celebrating its 18th anniversary on July 18, 2013 by offering a free consultation and proposal for a laboratory automation system. The company manufactures semi- to fully-automated dose content… Read more . . .
-
The US District Court for the Southern District of New York has issued a final judgment and order affirming the validity of five patents related to Mylan’s Perforomist formoterol fumarate inhalation solution and stating that… Read more . . .
-
According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn’s “profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)” and… Read more . . .
-
Trimel Pharmaceuticals has announced the acceptance of its NDA for CompleoTRT bioadhesive intranasal gel testosterone and the PDUFA date, February 28, 2014. The company announced submission of the NDA at the end of April 2013.… Read more . . .
-
According to RDD Online, the RDD China meeting scheduled to take place October 16-18, 2013 in Beijing has been cancelled due to “contractual problems which made it impossible for RDD to guarantee the quality of… Read more . . .
-
Inhaled pharmaceuticals company Prosonix has announced the appointment of Columbia Laboratories President and CEO Frank Condella as a Non-executive Director of Prosonix. Condella has held numerous position in the pharmaceutical industry, including as CEO of… Read more . . .
-
Avanir Pharmaceuticals has paid $20 million up front to OptiNose for an exclusive North American license for development and commercialization of OptiNose’s intranasal low-dose sumatriptan powder for the treatment of acute migraines. OptiNose could receive… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan